Hepatology News

Sodium-glucose cotransporter-2 inhibitors showed similar hepatic effectiveness to glucagon-like peptide-1 receptor agonists, especially among women and younger patients, in metabolic dysfunction-associated steatotic liver disease.

From 2010 to 2020, less than half of perinatally exposed infants were tested for hepatitis C virus, according to a study, but experts are hopeful that new early testing guidelines will ensure more infants are screened and treated.

Use of glucagon-like peptide-1 receptor agonists was associated with a reduced risk for progression to cirrhosis and other complications in patients with metabolic dysfunction-associated steatotic liver disease and diabetes, data showed.

The 2024 election is one of the most consequential elections in recent history, and as physicians, we have a responsibility to vote.

Most physicians and residents report feelings of burnout, while stigma about receiving mental health care remains prevalent, according to a new report from The Physicians Foundation.

Several notable guideline updates have been made in gastroenterology and hepatology for the diagnosis, management and treatment of GI and liver disorders. Wondering what you may have missed?

Most recipients of early liver transplant for severe alcohol-related liver disease live in close proximity to transplant centers, which are more likely to be in socially advantaged areas, according to research in Gastro Hep Advances.

Saving money at an early age is perhaps the simplest and one of the most effective methods to accumulate wealth.

The addition of lenvatinib and pembrolizumab to transarterial chemoembolization extended PFS for patients with intermediate-stage hepatocellular carcinoma, according to randomized phase 3 study results.

An FDA advisory committee voted against approval for obeticholic acid in primary biliary cholangitis without cirrhosis or compensated cirrhosis with portal hypertension, citing “concern for real possible harm”.